CUPR (CUPR): a likely value trap?

Avoid — a tiny, cash-burning maggot-therapy company whose stock is a pure speculative gamble, not an investment.

⚠ TRAP Fundamentals37/100

Down 94% from its all-time high of $65.68 — now $3.82

Why CUPR dropped

Shares spiked massively after an FDA 510(k) clearance for its "MEDIFLY Maggots" wound-care product in mid-June 2026 (up over 100% in a day), but the company just narrowly avoided Nasdaq delisting via a 1-for-8 reverse split weeks earlier, and the stock has been on a wild rollercoaster since, swinging between roughly $2 and $76 over the past year.

Fwd P/E —Op margin -10568.3%Rev growth 267.4%Debt/equity 67.5%Analyst upside —

How this scored 37/100 ❌ fails 2 hard checks

❌ Fails 2 hard checks — these are pass/fail and override the score entirely.

❌ Makes money not profitable (and no credible path to profit)

❌ Generates cash burns cash (free cash flow $-6M)

✅ Not drowning in debt Debt/equity 67.5% (limit 200%)

✅ Can pay its bills Current ratio 2.4 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 0/25

Operating margin -10568.3% 0/9

Net profit margin 0.0% 0/8

Return on equity -1569.1% 0/8

Growth Is it getting bigger, or dying? 14/25

Revenue growth 267.4% 9/9

Earnings growth unknown 2/8

Expected profit change unknown 2/8

Value Is it cheap right now? 8/25

Forward P/E unknown 3/10

PEG ratio unknown 2/8

Analyst target upside unknown 2/7

Balance sheet Will it survive? 15/25

Debt / equity 67.5% 7/10

Current ratio 2.4 7/8

Free cash flow $-6M 0/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for CUPR — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-21. Research only — not financial advice.